Biodexa Pharmaceuticals plc - American Depositary Shares (BDRX)
4.8090
+0.7390 (18.16%)
NASDAQ · Last Trade: Dec 10th, 12:44 PM EST
Detailed Quote
Previous Close
4.070
Open
5.000
Bid
4.810
Ask
4.820
Day's Range
4.760 - 5.750
52 Week Range
3.580 - 91.50
Volume
11,005,013
Market Cap
32.15B
PE Ratio (TTM)
-
EPS (TTM)
-
Dividend & Yield
N/A (N/A)
1 Month Average Volume
794,720
Chart
About Biodexa Pharmaceuticals plc - American Depositary Shares (BDRX)
Biodexa Pharmaceuticals is a biopharmaceutical company focused on advancing innovative therapies for the treatment of cancer and other serious diseases. The company specializes in developing proprietary drug delivery systems designed to enhance the therapeutic efficacy of existing drugs while minimizing side effects. By leveraging its expertise in nanomedicine and targeted delivery technologies, Biodexa strives to create safer, more effective treatment options to improve patient outcomes in oncology and beyond. Read More
Looking for insights into the US markets one hour before the close of the markets on Tuesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Wondering how the US markets performed in the middle of the day on Tuesday? Discover the movers and shakers of today's session in our comprehensive analysis.
As the US market prepares to open on Tuesday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
ENDRA Life Sciences (NASDAQ: NDRA) is redefining how emerging health-tech companies accelerate breakthrough innovation while maintaining disciplined capital efficiency. The developer of TAEUS® (Thermo-Acoustic Enhanced UltraSound) has implemented a modern treasury strategy managed by Arca Investment Management, converting idle cash into a structured, yield-generating engine that supports long-term growth without shareholder dilution.
After the conclusion of the US market's regular session on Monday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.
CARDIFF, UK / ACCESS Newswire / July 28, 2025 / Familial Adenomatous Polyposis (FAP) is an inherited condition that puts people at a much greater risk of developing colon cancer. If left untreated, there is a near 100% likelihood that the person will develop colon or rectum cancer. Despite the seriousness, there is no approved therapeutic option for treating FAP patients, and surgical resection of the colon and/or rectum remains the standard of care.
CARDIFF, UNITED KINGDOM / ACCESS Newswire / June 18, 2025 / When it comes to type 1 diabetes, treating this chronic condition can be difficult. After all, with this type of diabetes, the body's immune system attacks and destroys the beta cells that produce insulin. Without the natural ability to produce insulin, glucose from the bloodstream isn't absorbed into cells to provide energy. Since there is no cure, patients with type 1 diabetes need lifelong insulin therapy, typically via injections or a pump. Although type 1 diabetes typically develops in childhood or adolescence, it can happen at any age and is more likely to occur in individuals who are obese or inactive, or both. 1.7 million adults aged 20 or older - or 5.7% of U.S. adults - have the disease and are receiving insulin via shots or a pump.
